We recently published a list of 10 Stocks Insiders Sold in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other stocks that insiders sold in April after Trump’s tariff rollout.
Last week, President Donald Trump signed an executive order imposing a minimum 10% tariff on all U.S. imports, with certain exceptions. A 104% tariff on Chinese imports took effect, and Beijing said Wednesday it would raise levies on U.S. imports to 84% from 34%.
Treasury Secretary Scott Bessent told bankers that the economy is “in pretty good shape” while somewhat earlier JPMorgan chief Jamie Dimon expressed a more pessimistic view, warning that a recession could be on the horizon, according to the Wall Street Journal.
The Bank of England warned that US tariff announcements contribute to a “material increase in risks to global growth” and inflation levels, reports The Guardian.
Then, in an unexpected turn of events, the President announced Wednesday a complete three-month pause on all the “reciprocal” tariffs that went into effect with the exception of China.
Some insiders used this time in April to buy the dip while others thought it was time to sell some of their holdings. At times like these, it is worth analyzing insider trading activity. When executives buy stock, it can suggest confidence in the company’s future. On the other hand, insider sales don’t have to be a negative sign for the company, because they can reflect personal decisions or investment diversification. This means that insider trading should be considered alongside the company’s financial health and broader market conditions.
Our Methodology
Today, we’re focusing on stocks that insiders have been heavily selling in April. Using Insider Monkey’s insider trading screener, we identified companies where at least five insiders sold shares from April 2 to April 8. From this list, we ranked the top 10 stocks with the highest value of insider sales.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A doctor examining an X-ray or MRI scan to diagnose a neurological disorder.
Zai Lab Limited (NASDAQ:ZLAB)
Zai Lab Limited (NASDAQ:ZLAB) is a biopharmaceutical company focused on developing and commercializing treatments for oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula for ovarian cancer, VYVGART for myasthenia gravis, and NUZYRA for bacterial infections, among others. Headquartered in Shanghai, China, Zai Lab collaborates with various pharmaceutical companies to advance its pipeline of innovative therapies. It is also considered one of the 10 best performing growth stocks in 2025.
Recently, Zai Lab (NASDAQ:ZLAB) announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) to treat recurrent or metastatic cervical cancer. Dr. Rafael Amado, President of Global Research and Development, highlighted that TIVDAK could provide significant benefits for patients with limited treatment options. The results from the global clinical trial demonstrated a 45% reduction in the risk of death compared to chemotherapy in clinical trials.
This month, seven insiders, including the company’s CEO, and CFO, sold around $1.65 million worth of Zai Lab (NASDAQ:ZLAB) shares at an average price of $34.50 per share. Following these sales the stock price dropped to $25.13, losing 4.05% year-to-date. However, over the past 12 months, Zai Lab gained 56.87%.
According to TipRanks, five Wall Street analysts rate Zai Lab (NASDAQ:ZLAB) stock as a “Strong Buy” with a price target of $54.03 per share. This suggests a potential upside of 113.64% from the latest price.
Overall, ZLAB ranks 3rd on our list of stocks that insiders sold in April after Trump’s tariff rollout. While we acknowledge the potential of ZLAB, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ZLAB but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
